ArticleBJU international2026
The 5-year outcomes of a regional population-based PSA information and testing programme.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTo report descriptive outcomes including prostate-specific antigen (PSA) testing, diagnostic activity and diagnostic outcomes during the initial 5 years of a regional mailed PSA information and testing programme. SUBJECTS AND
methodsBetween 2015 and 2019 a letter regarding the pros and cons of PSA testing was sent to all men in the Värmland region of Sweden in every fifth year age group between 50 and 70 years. A total of 44 530 men were informed and instructed to contact their primary care centre if they wished to have a PSA test. Men with a PSA level ≥3 μg/L were referred to a urologist for evaluation. We used local and national registers to report trends in PSA testing, diagnostic activity, and diagnostic outcomes after programme implementation.
resultsAn average of 20% of informed men had a PSA test within 6 months, with increasing proportions over time. Among informed men, 3.5% had a PSA level ≥3 μg/L, 3.6% had a urology consultation, 1.5% underwent biopsies, and 0.8% were diagnosed with prostate cancer. [Correction added on 26 February 2026, after first online publication: The word 'tested' has been corrected to 'informed' in the preceding sentence.] The proportion who underwent magnetic resonance imaging was low. Between 2014 and 2017, the yearly number of PSA-tested men in the region increased from 4800 to 11 800 and the number of men undergoing prostate biopsies increased from 772 to 1217. Yearly prostate cancer incidence in the age group 50-74 years increased from 386 (2010-2013) to 659 cases/100 000 (2016-2019). We observed an increase mainly among intermediate- and low-risk tumours. At the end of the period, 80% of men in the older-age groups had had a PSA test during the preceding years.
conclusionsOrganising a population-based mailed PSA information programme combined with accessible testing in primary care is feasible on a regional scale in a Scandinavian healthcare setting and may reach high attendance. An observed increase in low-risk tumours inspires caution against programme implementation and highlights the importance of well-designed screening strategies and diagnostic algorithms to avoid over-detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.